Impact of containment and mitigation measures on children and youth with ASD during the COVID-19 pandemic: Report from the ELENA cohort.


Journal

Journal of psychiatric research
ISSN: 1879-1379
Titre abrégé: J Psychiatr Res
Pays: England
ID NLM: 0376331

Informations de publication

Date de publication:
05 2021
Historique:
received: 04 11 2020
revised: 04 02 2021
accepted: 17 02 2021
pubmed: 5 3 2021
medline: 11 5 2021
entrez: 4 3 2021
Statut: ppublish

Résumé

Containment, involving separation and restriction of movement of people due to the COVID-19 pandemic, and mitigation, also referred to as lockdown, involving closure of schools, universities and public venues, has had a profound impact on people's lives globally. The study focuses on the effects of containment and mitigation measures, on the behavior of children and youth (CaY) with Autism Spectrum Disorders (ASD). The study primary aim was to examine the impact of these urgent measures on the behaviors, communication, sleep, and nutritional status of the CaY. A secondary aim was to explore risk and protective factors on behavior change including sociodemographic variables, living conditions, ASD symptom severity and continuity of interventions. The study sample consisted of 239 ASD subjects, 2-21 years of age, enrolled in the ELENA cohort in France at Stage 3 confinement and mitigation measures announced on March 16, 2020. A parent informant completed the COVID-19 questionnaire. Of the domains examined, challenging behaviors, communicative skills and sleep had the greatest impact; in terms of risk and protective factors, subject age, ASD severity, single parenthood, daily living skills, and intervention continuity were most likely to impact behaviors; living conditions were not linked to behavior change. The findings highlight the topography of behavioral change in CaY with ASD following institution of containment and mitigation measures during the COVID-19 pandemic and help identify risk and protective factors to help better address needs and tailor interventions in the future.

Sections du résumé

BACKGROUND
Containment, involving separation and restriction of movement of people due to the COVID-19 pandemic, and mitigation, also referred to as lockdown, involving closure of schools, universities and public venues, has had a profound impact on people's lives globally. The study focuses on the effects of containment and mitigation measures, on the behavior of children and youth (CaY) with Autism Spectrum Disorders (ASD). The study primary aim was to examine the impact of these urgent measures on the behaviors, communication, sleep, and nutritional status of the CaY. A secondary aim was to explore risk and protective factors on behavior change including sociodemographic variables, living conditions, ASD symptom severity and continuity of interventions.
METHODS
The study sample consisted of 239 ASD subjects, 2-21 years of age, enrolled in the ELENA cohort in France at Stage 3 confinement and mitigation measures announced on March 16, 2020. A parent informant completed the COVID-19 questionnaire.
RESULTS
Of the domains examined, challenging behaviors, communicative skills and sleep had the greatest impact; in terms of risk and protective factors, subject age, ASD severity, single parenthood, daily living skills, and intervention continuity were most likely to impact behaviors; living conditions were not linked to behavior change.
CONCLUSIONS
The findings highlight the topography of behavioral change in CaY with ASD following institution of containment and mitigation measures during the COVID-19 pandemic and help identify risk and protective factors to help better address needs and tailor interventions in the future.

Identifiants

pubmed: 33662654
pii: S0022-3956(21)00119-9
doi: 10.1016/j.jpsychires.2021.02.041
pmc: PMC7898988
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02625116']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

73-80

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

Front Psychol. 2020 Jul 03;11:1713
pubmed: 32719646
Depress Anxiety. 2011 Mar;28(3):210-7
pubmed: 21394854
J Autism Dev Disord. 2020 Feb;50(2):455-466
pubmed: 31664612
J Neurodev Disord. 2014;6(1):44
pubmed: 25530819
Brain Sci. 2020 Jun 03;10(6):
pubmed: 32503172
J Am Acad Child Adolesc Psychiatry. 2008 Jun;47(6):642-651
pubmed: 18434924
Sleep Med. 2020 Nov;75:12-20
pubmed: 32853913
PLoS One. 2015 Nov 11;10(11):e0141703
pubmed: 26558765
N Engl J Med. 2020 Aug 6;383(6):510-512
pubmed: 32283003
BMJ. 2020 Jan 28;368:m313
pubmed: 31992552
J Pediatr Psychol. 2018 Aug 1;43(7):800-813
pubmed: 29701857
Indian J Pediatr. 2020 Jul;87(7):532-536
pubmed: 32472347
J Child Psychol Psychiatry. 2014 Jan;55(1):49-58
pubmed: 23848399
Ment Retard Dev Disabil Res Rev. 2007;13(1):16-25
pubmed: 17326115
Brain Sci. 2020 Jul 09;10(7):
pubmed: 32659945
Front Psychol. 2020 Nov 06;11:579038
pubmed: 33240167
Ir J Psychol Med. 2020 Sep;37(3):231-236
pubmed: 32404232
J Pediatr. 2020 Jun;221:264-266.e1
pubmed: 32248989
J Autism Dev Disord. 2012 Jul;42(7):1314-25
pubmed: 21928042
Disaster Med Public Health Prep. 2013 Feb;7(1):105-10
pubmed: 24618142
Lancet Respir Med. 2020 May;8(5):447-449
pubmed: 32222165
J Autism Dev Disord. 2019 May;49(5):2101-2115
pubmed: 30684086
J Trauma Stress. 2005 Oct;18(5):497-505
pubmed: 16281248
BMJ Open. 2019 Jun 19;9(6):e026286
pubmed: 31221874
Brain Sci. 2020 Apr 01;10(4):
pubmed: 32244776
Lancet. 2020 Mar 14;395(10227):912-920
pubmed: 32112714

Auteurs

Mathilde Berard (M)

Centre de Ressource Autisme Languedoc-Roussillon et Centre d'excellence sur l'autisme et les troubles neuro-développementaux, CHU Montpellier, Montpellier, France.

Cécile Rattaz (C)

Centre de Ressource Autisme Languedoc-Roussillon et Centre d'excellence sur l'autisme et les troubles neuro-développementaux, CHU Montpellier, Montpellier, France.

Marianne Peries (M)

Centre de Ressource Autisme Languedoc-Roussillon et Centre d'excellence sur l'autisme et les troubles neuro-développementaux, CHU Montpellier, Montpellier, France.

Julie Loubersac (J)

Centre de Ressource Autisme Languedoc-Roussillon et Centre d'excellence sur l'autisme et les troubles neuro-développementaux, CHU Montpellier, Montpellier, France; Université Paris-Saclay, UVSQ, Inserm, CESP, Team DevPsy, 94807, Villejuif, France.

Kerim Munir (K)

Developmental Medicine Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Amaria Baghdadli (A)

Centre de Ressource Autisme Languedoc-Roussillon et Centre d'excellence sur l'autisme et les troubles neuro-développementaux, CHU Montpellier, Montpellier, France; Université Paris-Saclay, UVSQ, Inserm, CESP, Team DevPsy, 94807, Villejuif, France; Faculté de Médecine, Université de Montpellier, France. Electronic address: rech-clinique-autisme@chu-montpellier.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH